New RNA therapy aims to reset immune system in severe autoimmune cases
NCT ID NCT07322718
Summary
This early-phase study is testing the safety and initial effects of an experimental treatment called RXIM002 for adults with severe autoimmune diseases that have returned or not improved with standard care. RXIM002 uses circular RNA technology to potentially reprogram the patient's own immune cells to target harmful B cells. The study will enroll 27 participants with conditions like lupus, scleroderma, or autoimmune blood disorders to monitor for side effects and see if the treatment shows any benefit.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B CELL-MEDIATED AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital
RECRUITINGShanghai, Huangpu District, No. 197, Ruijin 2nd Road, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.